Prostatic Neoplasm Clinical Trial
Official title:
Comparative Study of the Effects of Combined Spinal Anaesthesia and General Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy in Patients With Localised Prostate Cancer
Verified date | October 2022 |
Source | Sismanoglio General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prostate cancer is one of the most commonly diagnosed neoplasm in men worldwide. The gold standard of therapy is radical prostatectomy, a wide surgical excision of the neoplasm and can be performed either open, laparoscopic or robotic. The open retropubic approach, still performed today, can be completed under either general anaesthesia or combined (spinal/epidural) anaesthesia without any clear guideline on which one should be preferred. In this study the investigators aim to evaluate general anaesthesia and combined (spinal/ epidural) anaesthesia in patients undergoing open retropubic radical prostatectomy and define whether these may have an impact on the oncological outcome and safety of the procedure.
Status | Completed |
Enrollment | 60 |
Est. completion date | September 30, 2022 |
Est. primary completion date | August 31, 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Diagnosed with localised prostate cancer - Eligible for open retropubic radical prostatectomy Exclusion Criteria: - Metastatic prostate cancer - History of severe heart disease - History of haemostasis disorders - History of previous pelvic surgery - History of lung disease |
Country | Name | City | State |
---|---|---|---|
Greece | Sismanoglio General Hospital | Maroúsi | Attiki |
Lead Sponsor | Collaborator |
---|---|
Sismanoglio General Hospital | National and Kapodistrian University of Athens |
Greece,
Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322-30. — View Citation
Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. doi: 10.5435/JAAOSGlobal-D-17-00088. eCollection 2018 Mar. — View Citation
Gawande AA, Kwaan MR, Regenbogen SE, Lipsitz SA, Zinner MJ. An Apgar score for surgery. J Am Coll Surg. 2007 Feb;204(2):201-8. Epub 2006 Dec 27. — View Citation
Hatzinger M, Hubmann R, Moll F, Sohn M. [The history of prostate cancer from the beginning to DaVinci]. Aktuelle Urol. 2012 Jul;43(4):228-30. German. — View Citation
Hawthorne G, Sansoni J, Hayes L, Marosszeky N, Sansoni E. Measuring patient satisfaction with health care treatment using the Short Assessment of Patient Satisfaction measure delivered superior and robust satisfaction estimates. J Clin Epidemiol. 2014 May;67(5):527-37. doi: 10.1016/j.jclinepi.2013.12.010. — View Citation
Hinkelbein J, Lamperti M, Akeson J, Santos J, Costa J, De Robertis E, Longrois D, Novak-Jankovic V, Petrini F, Struys MMRF, Veyckemans F, Fuchs-Buder T, Fitzgerald R. European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults. Eur J Anaesthesiol. 2018 Jan;35(1):6-24. doi: 10.1097/EJA.0000000000000683. Review. — View Citation
Lepor H. A review of surgical techniques for radical prostatectomy. Rev Urol. 2005;7 Suppl 2:S11-7. — View Citation
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood Pressure Change | Measurement of patients systolic and diastolic blood pressure during the operation and post-operatively for 72 hours. | Peri-operatively | |
Primary | Heart Rate Change | Measurement of patients Heart Rate during the operation and post-operatively for 72 hours. | Peri-operatively | |
Primary | Surgical APGAR Score | Calculation of the Surgical APGAR score for each patient during surgery. The lower the score, on a scale of 1-10, the worst the prognosis of the patient.
SAS is calculated using three variables: Estimated blood loss (on a 0-3 scale, 0 points >1000 ml, 1 point 601-1000ml, 2 points 101-600 ml, 3 points <100ml) Lowest mean arterial pressure (on a 0-3 scale, 0 points <40 mmHg, 1 point 40-54 mmHg, 2 points 55-69 mmHg, 3 points >70 mmHg) Lowest heart rate (on a 0-4 scale, 0 points >85 bpm, 1 points 76-85 bpm, 2 points 66-75 bmp, 3 points 56-65 bmp, 4 points <55 bmp) during surgery. |
Peri-operatively | |
Primary | Blood Loss During Surgery | Measured from suction contents intra-operatively in ml | Peri-operatively | |
Primary | Haemoglobin Change | Haemoglobin measurement before the operation and at 12-, 24- and 48-hours post-operatively, in g/dL | Peri-operatively | |
Primary | Operation Time | Time required for:
Induction of anaesthesia Completion of the operation Post-operative time until the patient is successfully transferred to the recovery room |
Peri-operatively | |
Primary | Pain Assessed by the VAS Scale | Measured using a pain Visual Analogue Scale (VAS) at 6-, 24- and 48-hours after the operation.
VAS is a self-reporting pain scale based on a 0 to 10-point system, with each point measuring 10mm on a linear line. Every patient was asked to indicate his pain levels from "No Pain" (equals 0) to "Worst Pain Imaginable" (equals 10). |
Peri-operatively | |
Primary | Complication Rate | Complications related to the procedure:
Intraoperative bleeding Post-operative bleeding Bowel perforation Cardiovascular Respiratory Complications related to the anaesthesia technique performed: Post-operative headache Nausea and vomiting Any signs of potential nerve damage (manifested as inability to gain leg motility) |
Peri-operatively and up to 1 year after the operation | |
Primary | Change From Baseline PSA Levels at 6-months | Measurement of Prostatic Specific Antigen (PSA) levels at 6 to establish a PSA nadir value | 6 months post-operative | |
Primary | Change from 6-month PSA Levels at 12-months | Measurement of Prostatic Specific Antigen (PSA) levels at 12 post-operation to detect any biochemical recurrence | 12 months post-operative | |
Secondary | Change from Baseline Erectile Function after Radical Prostatectomy | Measured using the International Index of Erectile Function (IIEF-5) questionnaires pre-operatively and at 3-, 6- and 12-months post-surgery.
The test is composed of 5 questions with 5 points for each question. Patients are evaluated accordingly: Score 22 or more = No Erectile Disfunction Score 17-21 = Mild Erectile Disfunction Score 12-16 = Mild to moderate Erectile Disfunction Score 8-11 = Moderate Erectile Disfunction Score 7 or less = Severe Erectile Disfunction Results will be: Analysed and compared to evaluate any potential difference of the two methods of anaesthesia, on post-operational erectile function Analysed comparing pre-operation with post-operation questioners overall, to evaluate erectile disfunction after radical prostatectomy regardless of method of anaesthesia. |
Up to 1 year after the operation | |
Secondary | Post-operative Urinary Incontinence | Measured using the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form at 12 months post-surgery.
The Questionnaire is consisted of 4 questions: Frequency "How often do you leak urine?" on a scale of 0 (never) to 5 (all the time) Amount of leakage "How much urine do you leak?" on a scale to 0 (none) to 3 (a large amount) Overall impact on quality of life "How much does it interfere with your life?" on a scale of 0 (not at all) to 10 (a great deal) Timing of leakage "When does urine leak?" |
1 year after the operation | |
Secondary | Total Hospital Stay | Days until patient discharge from the hospital. | Peri-operative | |
Secondary | Patient Satisfaction Assessed by the Short Assessment of Patient Satisfaction (SAPS) Questionnaire | Satisfaction, using the Short Assessment of Patient Satisfaction (SAPS) Questionnaire, is measured in a scale of 0 to 28, with 0 to 10 equals to "Very Dissatisfied", 11-18 equals to "Dissatisfied", 19-26 equals to "Satisfied" and 27-28 equals to "Very Satisfied" | Peri-operative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03982095 -
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
|
||
Recruiting |
NCT05667636 -
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
|
Phase 2 | |
Terminated |
NCT01996696 -
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
|
Phase 2 | |
Completed |
NCT01431391 -
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT03289130 -
Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
|
||
Recruiting |
NCT04462926 -
Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
|
N/A | |
Completed |
NCT00001446 -
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
|
Phase 2 | |
Completed |
NCT02729103 -
Treatment Patterns in Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT00956228 -
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00247312 -
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
|
Phase 3 | |
Completed |
NCT00126854 -
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
|
N/A | |
Completed |
NCT00174863 -
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer
|
Phase 2 | |
Terminated |
NCT04221828 -
Trial of NanoPac Focal Therapy for Prostate Cancer
|
Phase 2 | |
Completed |
NCT00001266 -
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03935282 -
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
|
N/A | |
Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
Recruiting |
NCT06236789 -
Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
|
||
Completed |
NCT02977143 -
Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery
|
N/A | |
Completed |
NCT02966535 -
The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial
|
N/A | |
Completed |
NCT00252460 -
CT/MRI Co-registration Prostate Cancer
|
Phase 1 |